Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

Journal Articles

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138412

Published: 2020

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD

Blood (2018) 132 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2018-99-112076

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Blood (2018) 132 (Supplement 1): 343.

https://doi.org/10.1182/blood-2018-99-112450

Published: 2018

Journal Articles

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

Bjoern Chapuy, MD PhD, Chip Stewart, PhD, Andrew Dunford, MS, Jaegil Kim, PhD, Atanas Kamburow, PhD, Robert A. Redd, MS, Michael Lawrence, PhD, Margaretha G.M. Roemer, MSc, Amy Li, Marita Ziepert, PhD, Annette M. Staiger, PhD, Jeremiah Wala, Matthew D. Ducar, MS, Ignaty Leshchiner, PhD, Esther Rheinbay, PhD, Amaro Taylor-Weiner, BS, Caroline Coughlin, BS, Julian Hess, Chandra Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul van Hummelen, Andrew L Feldman, MD, Brian K Link, MD, Anne J Novak, PhD, James R. Cerhan, MD PhD, Thomas M Habermann, MD, Reiner Siebert, PhD, Andreas Rosenwald, Aaron R. Thorner, PhD, Matthew Meyerson, MDPhD, Todd R. Golub, MD, Rameen Beroukhim, Gerald Wulf, MD, German Ott, MD, Scott J. Rodig, MDPhD, Stefano Monti, PhD, Donna S. Neuberg, ScD, Markus Loeffler, MD, Michael Pfreundschuh, MD, Lorenz Trümper, MD, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2017) 130 (Supplement 1): 38.

https://doi.org/10.1182/blood.V130.Suppl_1.38.38

Published: 2017

Journal Articles

Dynamical Modeling of Clonal Evolution in Paired Primary and Relapsed Follicular Lymphoma Predicts a Link Between Cell Migration and Evolutionary Heterogeneity

Matthias Horn, PhD, Markus Kreuz, PhD, Ralf Küppers, PhD, Markus Loeffler, MD PhD

Blood (2016) 128 (22): 2929.

https://doi.org/10.1182/blood.V128.22.2929.2929

Published: 2016

Journal Articles

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

Blood (2016) 128 (22): 151.

https://doi.org/10.1182/blood.V128.22.151.151

Published: 2016

Journal Articles

Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP

Karin Hohloch, PD Dr., Bettina Altmann, Michael Pfreundschuh, MD, Markus Loeffler, Prof., Norbert Schmitz, MD, Marita Ziepert, PhD, Lorenz H. Truemper, MD PhD

Blood (2015) 126 (23): 1509.

https://doi.org/10.1182/blood.V126.23.1509.1509

Published: 2015

Journal Articles

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Kerry J. Savage, MDMSc, Samira Zeynalova, PhD, Roopesh R. Kansara, MD, Maike Nickelsen, MD, Diego Villa, MDMPH, Laurie H. Sehn, MDMPH, Marita Ziepert, David W. Scott, MBChB, PhD, Michael Pfreundschuh, MD PhD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Bertram Glass, MD, Markus Loeffler, Prof MDPhD, Norbert Schmitz

Blood (2014) 124 (21): 394.

https://doi.org/10.1182/blood.V124.21.394.394

Published: 2014

Journal Articles

Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint Analysis Of Two Prospective Phase III Randomized Trials Conducted By The Fondazione Italiana Linfomi (FIL) and The German High-Grade Lymphoma Study Group (DSHNHL)

Umberto Vitolo, MD, Marita Ziepert, Bertram Glass, Bettina Altmann, Annalisa Chiappella, Andrea Evangelista, Giovannino Ciccone, Pier Luigi Zinzani, Maike Nickelsen, Markus Loeffler, Maurizio Martelli, MD, Norbert Schmitz

Blood (2013) 122 (21): 4341.

https://doi.org/10.1182/blood.V122.21.4341.4341

Published: 2013

Journal Articles

Integrated Somatic Mutation and DNA Methylation Analysis Reveal Genomic and Epigenomic Co-Evolution In Follicular Lymphomas

Markus Loeffler, Prof MD PhD, Markus Kreuz, Andrea Haake, Dirk Hasenclever, PhD, Heiko Trautmann, PhD, Christian Arnold, Karsten Winter, Wolfram Klapper, René Scholtysik, Maciej Rosolowski, PhD, Steve Hoffmann, Ole Ammerpohl, Monika Szczepanowski, Dietrich Herrmann, Ralf Kueppers, Prof, Christiane Pott, M.D. Ph.D., Reiner Siebert, MD

Blood (2013) 122 (21): 502.

https://doi.org/10.1182/blood.V122.21.502.502

Published: 2013

Journal Articles

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Blood (2013) 121 (12): 2253–2263.

https://doi.org/10.1182/blood-2012-06-435842

Published: 2013

Journal Articles

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Matthias Horn, Ingmar Glauche, Martin C. Müller, Rüdiger Hehlmann, Andreas Hochhaus, Markus Loeffler, Ingo Roeder

Blood (2013) 121 (2): 378–384.

https://doi.org/10.1182/blood-2012-07-441956

Published: 2013

Includes: Supplemental data

Journal Articles

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Mathias Witzens-Harig, MD, Anthony D Ho, MD, Evelyn Kuhnt, Marek Trneny, MD, Michael Rieger, MD, Anders Österborg, MD, PhD, Ruth Pettengell, Robert Stevens, MD, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Jan Walewski, Markus Loeffler, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 1612.

https://doi.org/10.1182/blood.V120.21.1612.1612

Published: 2012

NARROW

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

Dynamical Modeling of Clonal Evolution in Paired Primary and Relapsed Follicular Lymphoma Predicts a Link Between Cell Migration and Evolutionary Heterogeneity

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Integrated Somatic Mutation and DNA Methylation Analysis Reveal Genomic and Epigenomic Co-Evolution In Follicular Lymphomas

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only